A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN.

Trial Profile

A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2011

At a glance

  • Drugs AZD 4877 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Sep 2007 Status changed from recruiting to discontinued.
    • 22 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top